<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE LCTL_TEXT SYSTEM "ltf.v1.5.dtd">
<LCTL_TEXT lang="spa">
<DOC id="L0C04CVNC" lang="spa" tokenization="tokenization_parameters.v5.0" grammar="none" raw_text_char_length="3929" raw_text_md5="e2c2867cab6f73bcd60f41af7236aa97">
<TEXT>
<SEG id="segment-0" start_char="1" end_char="67">
<ORIGINAL_TEXT>Sofosbuvir/daclatasvir drugs may be effective coronavirus treatment</ORIGINAL_TEXT>
<TOKEN id="token-0-0" pos="unknown" morph="none" start_char="1" end_char="22">Sofosbuvir/daclatasvir</TOKEN>
<TOKEN id="token-0-1" pos="word" morph="none" start_char="24" end_char="28">drugs</TOKEN>
<TOKEN id="token-0-2" pos="word" morph="none" start_char="30" end_char="32">may</TOKEN>
<TOKEN id="token-0-3" pos="word" morph="none" start_char="34" end_char="35">be</TOKEN>
<TOKEN id="token-0-4" pos="word" morph="none" start_char="37" end_char="45">effective</TOKEN>
<TOKEN id="token-0-5" pos="word" morph="none" start_char="47" end_char="57">coronavirus</TOKEN>
<TOKEN id="token-0-6" pos="word" morph="none" start_char="59" end_char="67">treatment</TOKEN>
</SEG>
<SEG id="segment-1" start_char="71" end_char="91">
<ORIGINAL_TEXT>Several new papers in</ORIGINAL_TEXT>
<TOKEN id="token-1-0" pos="word" morph="none" start_char="71" end_char="77">Several</TOKEN>
<TOKEN id="token-1-1" pos="word" morph="none" start_char="79" end_char="81">new</TOKEN>
<TOKEN id="token-1-2" pos="word" morph="none" start_char="83" end_char="88">papers</TOKEN>
<TOKEN id="token-1-3" pos="word" morph="none" start_char="90" end_char="91">in</TOKEN>
</SEG>
<SEG id="segment-2" start_char="94" end_char="130">
<ORIGINAL_TEXT>Journal of Antimicrobial Chemotherapy</ORIGINAL_TEXT>
<TOKEN id="token-2-0" pos="word" morph="none" start_char="94" end_char="100">Journal</TOKEN>
<TOKEN id="token-2-1" pos="word" morph="none" start_char="102" end_char="103">of</TOKEN>
<TOKEN id="token-2-2" pos="word" morph="none" start_char="105" end_char="117">Antimicrobial</TOKEN>
<TOKEN id="token-2-3" pos="word" morph="none" start_char="119" end_char="130">Chemotherapy</TOKEN>
</SEG>
<SEG id="segment-3" start_char="133" end_char="215">
<ORIGINAL_TEXT>, published by Oxford University Press, suggest successful treatments for COVID-19.</ORIGINAL_TEXT>
<TOKEN id="token-3-0" pos="punct" morph="none" start_char="133" end_char="133">,</TOKEN>
<TOKEN id="token-3-1" pos="word" morph="none" start_char="135" end_char="143">published</TOKEN>
<TOKEN id="token-3-2" pos="word" morph="none" start_char="145" end_char="146">by</TOKEN>
<TOKEN id="token-3-3" pos="word" morph="none" start_char="148" end_char="153">Oxford</TOKEN>
<TOKEN id="token-3-4" pos="word" morph="none" start_char="155" end_char="164">University</TOKEN>
<TOKEN id="token-3-5" pos="word" morph="none" start_char="166" end_char="170">Press</TOKEN>
<TOKEN id="token-3-6" pos="punct" morph="none" start_char="171" end_char="171">,</TOKEN>
<TOKEN id="token-3-7" pos="word" morph="none" start_char="173" end_char="179">suggest</TOKEN>
<TOKEN id="token-3-8" pos="word" morph="none" start_char="181" end_char="190">successful</TOKEN>
<TOKEN id="token-3-9" pos="word" morph="none" start_char="192" end_char="201">treatments</TOKEN>
<TOKEN id="token-3-10" pos="word" morph="none" start_char="203" end_char="205">for</TOKEN>
<TOKEN id="token-3-11" pos="unknown" morph="none" start_char="207" end_char="214">COVID-19</TOKEN>
<TOKEN id="token-3-12" pos="punct" morph="none" start_char="215" end_char="215">.</TOKEN>
</SEG>
<SEG id="segment-4" start_char="218" end_char="315">
<ORIGINAL_TEXT>Three articles all researched the use of sofosbuvir and daclatasvir for the treatment of COVID-19.</ORIGINAL_TEXT>
<TOKEN id="token-4-0" pos="word" morph="none" start_char="218" end_char="222">Three</TOKEN>
<TOKEN id="token-4-1" pos="word" morph="none" start_char="224" end_char="231">articles</TOKEN>
<TOKEN id="token-4-2" pos="word" morph="none" start_char="233" end_char="235">all</TOKEN>
<TOKEN id="token-4-3" pos="word" morph="none" start_char="237" end_char="246">researched</TOKEN>
<TOKEN id="token-4-4" pos="word" morph="none" start_char="248" end_char="250">the</TOKEN>
<TOKEN id="token-4-5" pos="word" morph="none" start_char="252" end_char="254">use</TOKEN>
<TOKEN id="token-4-6" pos="word" morph="none" start_char="256" end_char="257">of</TOKEN>
<TOKEN id="token-4-7" pos="word" morph="none" start_char="259" end_char="268">sofosbuvir</TOKEN>
<TOKEN id="token-4-8" pos="word" morph="none" start_char="270" end_char="272">and</TOKEN>
<TOKEN id="token-4-9" pos="word" morph="none" start_char="274" end_char="284">daclatasvir</TOKEN>
<TOKEN id="token-4-10" pos="word" morph="none" start_char="286" end_char="288">for</TOKEN>
<TOKEN id="token-4-11" pos="word" morph="none" start_char="290" end_char="292">the</TOKEN>
<TOKEN id="token-4-12" pos="word" morph="none" start_char="294" end_char="302">treatment</TOKEN>
<TOKEN id="token-4-13" pos="word" morph="none" start_char="304" end_char="305">of</TOKEN>
<TOKEN id="token-4-14" pos="unknown" morph="none" start_char="307" end_char="314">COVID-19</TOKEN>
<TOKEN id="token-4-15" pos="punct" morph="none" start_char="315" end_char="315">.</TOKEN>
</SEG>
<SEG id="segment-5" start_char="317" end_char="571">
<ORIGINAL_TEXT>These three papers come from Iran, which has developed its own pill containing sofosbuvir and daclatasvir, and is in a position to test this in a large clinical trial as Iran is a massively impacted country, reporting some 2500 cases and 200 deaths a day.</ORIGINAL_TEXT>
<TOKEN id="token-5-0" pos="word" morph="none" start_char="317" end_char="321">These</TOKEN>
<TOKEN id="token-5-1" pos="word" morph="none" start_char="323" end_char="327">three</TOKEN>
<TOKEN id="token-5-2" pos="word" morph="none" start_char="329" end_char="334">papers</TOKEN>
<TOKEN id="token-5-3" pos="word" morph="none" start_char="336" end_char="339">come</TOKEN>
<TOKEN id="token-5-4" pos="word" morph="none" start_char="341" end_char="344">from</TOKEN>
<TOKEN id="token-5-5" pos="word" morph="none" start_char="346" end_char="349">Iran</TOKEN>
<TOKEN id="token-5-6" pos="punct" morph="none" start_char="350" end_char="350">,</TOKEN>
<TOKEN id="token-5-7" pos="word" morph="none" start_char="352" end_char="356">which</TOKEN>
<TOKEN id="token-5-8" pos="word" morph="none" start_char="358" end_char="360">has</TOKEN>
<TOKEN id="token-5-9" pos="word" morph="none" start_char="362" end_char="370">developed</TOKEN>
<TOKEN id="token-5-10" pos="word" morph="none" start_char="372" end_char="374">its</TOKEN>
<TOKEN id="token-5-11" pos="word" morph="none" start_char="376" end_char="378">own</TOKEN>
<TOKEN id="token-5-12" pos="word" morph="none" start_char="380" end_char="383">pill</TOKEN>
<TOKEN id="token-5-13" pos="word" morph="none" start_char="385" end_char="394">containing</TOKEN>
<TOKEN id="token-5-14" pos="word" morph="none" start_char="396" end_char="405">sofosbuvir</TOKEN>
<TOKEN id="token-5-15" pos="word" morph="none" start_char="407" end_char="409">and</TOKEN>
<TOKEN id="token-5-16" pos="word" morph="none" start_char="411" end_char="421">daclatasvir</TOKEN>
<TOKEN id="token-5-17" pos="punct" morph="none" start_char="422" end_char="422">,</TOKEN>
<TOKEN id="token-5-18" pos="word" morph="none" start_char="424" end_char="426">and</TOKEN>
<TOKEN id="token-5-19" pos="word" morph="none" start_char="428" end_char="429">is</TOKEN>
<TOKEN id="token-5-20" pos="word" morph="none" start_char="431" end_char="432">in</TOKEN>
<TOKEN id="token-5-21" pos="word" morph="none" start_char="434" end_char="434">a</TOKEN>
<TOKEN id="token-5-22" pos="word" morph="none" start_char="436" end_char="443">position</TOKEN>
<TOKEN id="token-5-23" pos="word" morph="none" start_char="445" end_char="446">to</TOKEN>
<TOKEN id="token-5-24" pos="word" morph="none" start_char="448" end_char="451">test</TOKEN>
<TOKEN id="token-5-25" pos="word" morph="none" start_char="453" end_char="456">this</TOKEN>
<TOKEN id="token-5-26" pos="word" morph="none" start_char="458" end_char="459">in</TOKEN>
<TOKEN id="token-5-27" pos="word" morph="none" start_char="461" end_char="461">a</TOKEN>
<TOKEN id="token-5-28" pos="word" morph="none" start_char="463" end_char="467">large</TOKEN>
<TOKEN id="token-5-29" pos="word" morph="none" start_char="469" end_char="476">clinical</TOKEN>
<TOKEN id="token-5-30" pos="word" morph="none" start_char="478" end_char="482">trial</TOKEN>
<TOKEN id="token-5-31" pos="word" morph="none" start_char="484" end_char="485">as</TOKEN>
<TOKEN id="token-5-32" pos="word" morph="none" start_char="487" end_char="490">Iran</TOKEN>
<TOKEN id="token-5-33" pos="word" morph="none" start_char="492" end_char="493">is</TOKEN>
<TOKEN id="token-5-34" pos="word" morph="none" start_char="495" end_char="495">a</TOKEN>
<TOKEN id="token-5-35" pos="word" morph="none" start_char="497" end_char="505">massively</TOKEN>
<TOKEN id="token-5-36" pos="word" morph="none" start_char="507" end_char="514">impacted</TOKEN>
<TOKEN id="token-5-37" pos="word" morph="none" start_char="516" end_char="522">country</TOKEN>
<TOKEN id="token-5-38" pos="punct" morph="none" start_char="523" end_char="523">,</TOKEN>
<TOKEN id="token-5-39" pos="word" morph="none" start_char="525" end_char="533">reporting</TOKEN>
<TOKEN id="token-5-40" pos="word" morph="none" start_char="535" end_char="538">some</TOKEN>
<TOKEN id="token-5-41" pos="word" morph="none" start_char="540" end_char="543">2500</TOKEN>
<TOKEN id="token-5-42" pos="word" morph="none" start_char="545" end_char="549">cases</TOKEN>
<TOKEN id="token-5-43" pos="word" morph="none" start_char="551" end_char="553">and</TOKEN>
<TOKEN id="token-5-44" pos="word" morph="none" start_char="555" end_char="557">200</TOKEN>
<TOKEN id="token-5-45" pos="word" morph="none" start_char="559" end_char="564">deaths</TOKEN>
<TOKEN id="token-5-46" pos="word" morph="none" start_char="566" end_char="566">a</TOKEN>
<TOKEN id="token-5-47" pos="word" morph="none" start_char="568" end_char="570">day</TOKEN>
<TOKEN id="token-5-48" pos="punct" morph="none" start_char="571" end_char="571">.</TOKEN>
</SEG>
<SEG id="segment-6" start_char="574" end_char="647">
<ORIGINAL_TEXT>Currently no effective antiviral therapy has been found to treat COVID-19.</ORIGINAL_TEXT>
<TOKEN id="token-6-0" pos="word" morph="none" start_char="574" end_char="582">Currently</TOKEN>
<TOKEN id="token-6-1" pos="word" morph="none" start_char="584" end_char="585">no</TOKEN>
<TOKEN id="token-6-2" pos="word" morph="none" start_char="587" end_char="595">effective</TOKEN>
<TOKEN id="token-6-3" pos="word" morph="none" start_char="597" end_char="605">antiviral</TOKEN>
<TOKEN id="token-6-4" pos="word" morph="none" start_char="607" end_char="613">therapy</TOKEN>
<TOKEN id="token-6-5" pos="word" morph="none" start_char="615" end_char="617">has</TOKEN>
<TOKEN id="token-6-6" pos="word" morph="none" start_char="619" end_char="622">been</TOKEN>
<TOKEN id="token-6-7" pos="word" morph="none" start_char="624" end_char="628">found</TOKEN>
<TOKEN id="token-6-8" pos="word" morph="none" start_char="630" end_char="631">to</TOKEN>
<TOKEN id="token-6-9" pos="word" morph="none" start_char="633" end_char="637">treat</TOKEN>
<TOKEN id="token-6-10" pos="unknown" morph="none" start_char="639" end_char="646">COVID-19</TOKEN>
<TOKEN id="token-6-11" pos="punct" morph="none" start_char="647" end_char="647">.</TOKEN>
</SEG>
<SEG id="segment-7" start_char="649" end_char="870">
<ORIGINAL_TEXT>The aim of the trials was to assess if the addition of sofosbuvir and daclatasvir, a drug combination commonly used for the treatment of hepatitis C, improved clinical outcomes in patients with moderate or severe COVID-19.</ORIGINAL_TEXT>
<TOKEN id="token-7-0" pos="word" morph="none" start_char="649" end_char="651">The</TOKEN>
<TOKEN id="token-7-1" pos="word" morph="none" start_char="653" end_char="655">aim</TOKEN>
<TOKEN id="token-7-2" pos="word" morph="none" start_char="657" end_char="658">of</TOKEN>
<TOKEN id="token-7-3" pos="word" morph="none" start_char="660" end_char="662">the</TOKEN>
<TOKEN id="token-7-4" pos="word" morph="none" start_char="664" end_char="669">trials</TOKEN>
<TOKEN id="token-7-5" pos="word" morph="none" start_char="671" end_char="673">was</TOKEN>
<TOKEN id="token-7-6" pos="word" morph="none" start_char="675" end_char="676">to</TOKEN>
<TOKEN id="token-7-7" pos="word" morph="none" start_char="678" end_char="683">assess</TOKEN>
<TOKEN id="token-7-8" pos="word" morph="none" start_char="685" end_char="686">if</TOKEN>
<TOKEN id="token-7-9" pos="word" morph="none" start_char="688" end_char="690">the</TOKEN>
<TOKEN id="token-7-10" pos="word" morph="none" start_char="692" end_char="699">addition</TOKEN>
<TOKEN id="token-7-11" pos="word" morph="none" start_char="701" end_char="702">of</TOKEN>
<TOKEN id="token-7-12" pos="word" morph="none" start_char="704" end_char="713">sofosbuvir</TOKEN>
<TOKEN id="token-7-13" pos="word" morph="none" start_char="715" end_char="717">and</TOKEN>
<TOKEN id="token-7-14" pos="word" morph="none" start_char="719" end_char="729">daclatasvir</TOKEN>
<TOKEN id="token-7-15" pos="punct" morph="none" start_char="730" end_char="730">,</TOKEN>
<TOKEN id="token-7-16" pos="word" morph="none" start_char="732" end_char="732">a</TOKEN>
<TOKEN id="token-7-17" pos="word" morph="none" start_char="734" end_char="737">drug</TOKEN>
<TOKEN id="token-7-18" pos="word" morph="none" start_char="739" end_char="749">combination</TOKEN>
<TOKEN id="token-7-19" pos="word" morph="none" start_char="751" end_char="758">commonly</TOKEN>
<TOKEN id="token-7-20" pos="word" morph="none" start_char="760" end_char="763">used</TOKEN>
<TOKEN id="token-7-21" pos="word" morph="none" start_char="765" end_char="767">for</TOKEN>
<TOKEN id="token-7-22" pos="word" morph="none" start_char="769" end_char="771">the</TOKEN>
<TOKEN id="token-7-23" pos="word" morph="none" start_char="773" end_char="781">treatment</TOKEN>
<TOKEN id="token-7-24" pos="word" morph="none" start_char="783" end_char="784">of</TOKEN>
<TOKEN id="token-7-25" pos="word" morph="none" start_char="786" end_char="794">hepatitis</TOKEN>
<TOKEN id="token-7-26" pos="word" morph="none" start_char="796" end_char="796">C</TOKEN>
<TOKEN id="token-7-27" pos="punct" morph="none" start_char="797" end_char="797">,</TOKEN>
<TOKEN id="token-7-28" pos="word" morph="none" start_char="799" end_char="806">improved</TOKEN>
<TOKEN id="token-7-29" pos="word" morph="none" start_char="808" end_char="815">clinical</TOKEN>
<TOKEN id="token-7-30" pos="word" morph="none" start_char="817" end_char="824">outcomes</TOKEN>
<TOKEN id="token-7-31" pos="word" morph="none" start_char="826" end_char="827">in</TOKEN>
<TOKEN id="token-7-32" pos="word" morph="none" start_char="829" end_char="836">patients</TOKEN>
<TOKEN id="token-7-33" pos="word" morph="none" start_char="838" end_char="841">with</TOKEN>
<TOKEN id="token-7-34" pos="word" morph="none" start_char="843" end_char="850">moderate</TOKEN>
<TOKEN id="token-7-35" pos="word" morph="none" start_char="852" end_char="853">or</TOKEN>
<TOKEN id="token-7-36" pos="word" morph="none" start_char="855" end_char="860">severe</TOKEN>
<TOKEN id="token-7-37" pos="unknown" morph="none" start_char="862" end_char="869">COVID-19</TOKEN>
<TOKEN id="token-7-38" pos="punct" morph="none" start_char="870" end_char="870">.</TOKEN>
</SEG>
<SEG id="segment-8" start_char="873" end_char="990">
<ORIGINAL_TEXT>In one trial, researchers recruited 66 patients and allocated them to either the treatment group or the control group.</ORIGINAL_TEXT>
<TOKEN id="token-8-0" pos="word" morph="none" start_char="873" end_char="874">In</TOKEN>
<TOKEN id="token-8-1" pos="word" morph="none" start_char="876" end_char="878">one</TOKEN>
<TOKEN id="token-8-2" pos="word" morph="none" start_char="880" end_char="884">trial</TOKEN>
<TOKEN id="token-8-3" pos="punct" morph="none" start_char="885" end_char="885">,</TOKEN>
<TOKEN id="token-8-4" pos="word" morph="none" start_char="887" end_char="897">researchers</TOKEN>
<TOKEN id="token-8-5" pos="word" morph="none" start_char="899" end_char="907">recruited</TOKEN>
<TOKEN id="token-8-6" pos="word" morph="none" start_char="909" end_char="910">66</TOKEN>
<TOKEN id="token-8-7" pos="word" morph="none" start_char="912" end_char="919">patients</TOKEN>
<TOKEN id="token-8-8" pos="word" morph="none" start_char="921" end_char="923">and</TOKEN>
<TOKEN id="token-8-9" pos="word" morph="none" start_char="925" end_char="933">allocated</TOKEN>
<TOKEN id="token-8-10" pos="word" morph="none" start_char="935" end_char="938">them</TOKEN>
<TOKEN id="token-8-11" pos="word" morph="none" start_char="940" end_char="941">to</TOKEN>
<TOKEN id="token-8-12" pos="word" morph="none" start_char="943" end_char="948">either</TOKEN>
<TOKEN id="token-8-13" pos="word" morph="none" start_char="950" end_char="952">the</TOKEN>
<TOKEN id="token-8-14" pos="word" morph="none" start_char="954" end_char="962">treatment</TOKEN>
<TOKEN id="token-8-15" pos="word" morph="none" start_char="964" end_char="968">group</TOKEN>
<TOKEN id="token-8-16" pos="word" morph="none" start_char="970" end_char="971">or</TOKEN>
<TOKEN id="token-8-17" pos="word" morph="none" start_char="973" end_char="975">the</TOKEN>
<TOKEN id="token-8-18" pos="word" morph="none" start_char="977" end_char="983">control</TOKEN>
<TOKEN id="token-8-19" pos="word" morph="none" start_char="985" end_char="989">group</TOKEN>
<TOKEN id="token-8-20" pos="punct" morph="none" start_char="990" end_char="990">.</TOKEN>
</SEG>
<SEG id="segment-9" start_char="992" end_char="1096">
<ORIGINAL_TEXT>Clinical recovery within 14 days was achieved by 88% in the treatment group and 67% in the control group.</ORIGINAL_TEXT>
<TOKEN id="token-9-0" pos="word" morph="none" start_char="992" end_char="999">Clinical</TOKEN>
<TOKEN id="token-9-1" pos="word" morph="none" start_char="1001" end_char="1008">recovery</TOKEN>
<TOKEN id="token-9-2" pos="word" morph="none" start_char="1010" end_char="1015">within</TOKEN>
<TOKEN id="token-9-3" pos="word" morph="none" start_char="1017" end_char="1018">14</TOKEN>
<TOKEN id="token-9-4" pos="word" morph="none" start_char="1020" end_char="1023">days</TOKEN>
<TOKEN id="token-9-5" pos="word" morph="none" start_char="1025" end_char="1027">was</TOKEN>
<TOKEN id="token-9-6" pos="word" morph="none" start_char="1029" end_char="1036">achieved</TOKEN>
<TOKEN id="token-9-7" pos="word" morph="none" start_char="1038" end_char="1039">by</TOKEN>
<TOKEN id="token-9-8" pos="word" morph="none" start_char="1041" end_char="1042">88</TOKEN>
<TOKEN id="token-9-9" pos="punct" morph="none" start_char="1043" end_char="1043">%</TOKEN>
<TOKEN id="token-9-10" pos="word" morph="none" start_char="1045" end_char="1046">in</TOKEN>
<TOKEN id="token-9-11" pos="word" morph="none" start_char="1048" end_char="1050">the</TOKEN>
<TOKEN id="token-9-12" pos="word" morph="none" start_char="1052" end_char="1060">treatment</TOKEN>
<TOKEN id="token-9-13" pos="word" morph="none" start_char="1062" end_char="1066">group</TOKEN>
<TOKEN id="token-9-14" pos="word" morph="none" start_char="1068" end_char="1070">and</TOKEN>
<TOKEN id="token-9-15" pos="word" morph="none" start_char="1072" end_char="1073">67</TOKEN>
<TOKEN id="token-9-16" pos="punct" morph="none" start_char="1074" end_char="1074">%</TOKEN>
<TOKEN id="token-9-17" pos="word" morph="none" start_char="1076" end_char="1077">in</TOKEN>
<TOKEN id="token-9-18" pos="word" morph="none" start_char="1079" end_char="1081">the</TOKEN>
<TOKEN id="token-9-19" pos="word" morph="none" start_char="1083" end_char="1089">control</TOKEN>
<TOKEN id="token-9-20" pos="word" morph="none" start_char="1091" end_char="1095">group</TOKEN>
<TOKEN id="token-9-21" pos="punct" morph="none" start_char="1096" end_char="1096">.</TOKEN>
</SEG>
<SEG id="segment-10" start_char="1098" end_char="1221">
<ORIGINAL_TEXT>The treatment group had a significantly shorter median duration of hospitalization (6 days) than the control group (8 days).</ORIGINAL_TEXT>
<TOKEN id="token-10-0" pos="word" morph="none" start_char="1098" end_char="1100">The</TOKEN>
<TOKEN id="token-10-1" pos="word" morph="none" start_char="1102" end_char="1110">treatment</TOKEN>
<TOKEN id="token-10-2" pos="word" morph="none" start_char="1112" end_char="1116">group</TOKEN>
<TOKEN id="token-10-3" pos="word" morph="none" start_char="1118" end_char="1120">had</TOKEN>
<TOKEN id="token-10-4" pos="word" morph="none" start_char="1122" end_char="1122">a</TOKEN>
<TOKEN id="token-10-5" pos="word" morph="none" start_char="1124" end_char="1136">significantly</TOKEN>
<TOKEN id="token-10-6" pos="word" morph="none" start_char="1138" end_char="1144">shorter</TOKEN>
<TOKEN id="token-10-7" pos="word" morph="none" start_char="1146" end_char="1151">median</TOKEN>
<TOKEN id="token-10-8" pos="word" morph="none" start_char="1153" end_char="1160">duration</TOKEN>
<TOKEN id="token-10-9" pos="word" morph="none" start_char="1162" end_char="1163">of</TOKEN>
<TOKEN id="token-10-10" pos="word" morph="none" start_char="1165" end_char="1179">hospitalization</TOKEN>
<TOKEN id="token-10-11" pos="punct" morph="none" start_char="1181" end_char="1181">(</TOKEN>
<TOKEN id="token-10-12" pos="word" morph="none" start_char="1182" end_char="1182">6</TOKEN>
<TOKEN id="token-10-13" pos="word" morph="none" start_char="1184" end_char="1187">days</TOKEN>
<TOKEN id="token-10-14" pos="punct" morph="none" start_char="1188" end_char="1188">)</TOKEN>
<TOKEN id="token-10-15" pos="word" morph="none" start_char="1190" end_char="1193">than</TOKEN>
<TOKEN id="token-10-16" pos="word" morph="none" start_char="1195" end_char="1197">the</TOKEN>
<TOKEN id="token-10-17" pos="word" morph="none" start_char="1199" end_char="1205">control</TOKEN>
<TOKEN id="token-10-18" pos="word" morph="none" start_char="1207" end_char="1211">group</TOKEN>
<TOKEN id="token-10-19" pos="punct" morph="none" start_char="1213" end_char="1213">(</TOKEN>
<TOKEN id="token-10-20" pos="word" morph="none" start_char="1214" end_char="1214">8</TOKEN>
<TOKEN id="token-10-21" pos="word" morph="none" start_char="1216" end_char="1219">days</TOKEN>
<TOKEN id="token-10-22" pos="punct" morph="none" start_char="1220" end_char="1221">).</TOKEN>
</SEG>
<SEG id="segment-11" start_char="1223" end_char="1328">
<ORIGINAL_TEXT>Cumulative incidence of hospital discharge was significantly higher in the treatment group versus control.</ORIGINAL_TEXT>
<TOKEN id="token-11-0" pos="word" morph="none" start_char="1223" end_char="1232">Cumulative</TOKEN>
<TOKEN id="token-11-1" pos="word" morph="none" start_char="1234" end_char="1242">incidence</TOKEN>
<TOKEN id="token-11-2" pos="word" morph="none" start_char="1244" end_char="1245">of</TOKEN>
<TOKEN id="token-11-3" pos="word" morph="none" start_char="1247" end_char="1254">hospital</TOKEN>
<TOKEN id="token-11-4" pos="word" morph="none" start_char="1256" end_char="1264">discharge</TOKEN>
<TOKEN id="token-11-5" pos="word" morph="none" start_char="1266" end_char="1268">was</TOKEN>
<TOKEN id="token-11-6" pos="word" morph="none" start_char="1270" end_char="1282">significantly</TOKEN>
<TOKEN id="token-11-7" pos="word" morph="none" start_char="1284" end_char="1289">higher</TOKEN>
<TOKEN id="token-11-8" pos="word" morph="none" start_char="1291" end_char="1292">in</TOKEN>
<TOKEN id="token-11-9" pos="word" morph="none" start_char="1294" end_char="1296">the</TOKEN>
<TOKEN id="token-11-10" pos="word" morph="none" start_char="1298" end_char="1306">treatment</TOKEN>
<TOKEN id="token-11-11" pos="word" morph="none" start_char="1308" end_char="1312">group</TOKEN>
<TOKEN id="token-11-12" pos="word" morph="none" start_char="1314" end_char="1319">versus</TOKEN>
<TOKEN id="token-11-13" pos="word" morph="none" start_char="1321" end_char="1327">control</TOKEN>
<TOKEN id="token-11-14" pos="punct" morph="none" start_char="1328" end_char="1328">.</TOKEN>
</SEG>
<SEG id="segment-12" start_char="1330" end_char="1402">
<ORIGINAL_TEXT>Three patients died in the treatment group and five in the control group.</ORIGINAL_TEXT>
<TOKEN id="token-12-0" pos="word" morph="none" start_char="1330" end_char="1334">Three</TOKEN>
<TOKEN id="token-12-1" pos="word" morph="none" start_char="1336" end_char="1343">patients</TOKEN>
<TOKEN id="token-12-2" pos="word" morph="none" start_char="1345" end_char="1348">died</TOKEN>
<TOKEN id="token-12-3" pos="word" morph="none" start_char="1350" end_char="1351">in</TOKEN>
<TOKEN id="token-12-4" pos="word" morph="none" start_char="1353" end_char="1355">the</TOKEN>
<TOKEN id="token-12-5" pos="word" morph="none" start_char="1357" end_char="1365">treatment</TOKEN>
<TOKEN id="token-12-6" pos="word" morph="none" start_char="1367" end_char="1371">group</TOKEN>
<TOKEN id="token-12-7" pos="word" morph="none" start_char="1373" end_char="1375">and</TOKEN>
<TOKEN id="token-12-8" pos="word" morph="none" start_char="1377" end_char="1380">five</TOKEN>
<TOKEN id="token-12-9" pos="word" morph="none" start_char="1382" end_char="1383">in</TOKEN>
<TOKEN id="token-12-10" pos="word" morph="none" start_char="1385" end_char="1387">the</TOKEN>
<TOKEN id="token-12-11" pos="word" morph="none" start_char="1389" end_char="1395">control</TOKEN>
<TOKEN id="token-12-12" pos="word" morph="none" start_char="1397" end_char="1401">group</TOKEN>
<TOKEN id="token-12-13" pos="punct" morph="none" start_char="1402" end_char="1402">.</TOKEN>
</SEG>
<SEG id="segment-13" start_char="1404" end_char="1443">
<ORIGINAL_TEXT>No serious adverse events were reported.</ORIGINAL_TEXT>
<TOKEN id="token-13-0" pos="word" morph="none" start_char="1404" end_char="1405">No</TOKEN>
<TOKEN id="token-13-1" pos="word" morph="none" start_char="1407" end_char="1413">serious</TOKEN>
<TOKEN id="token-13-2" pos="word" morph="none" start_char="1415" end_char="1421">adverse</TOKEN>
<TOKEN id="token-13-3" pos="word" morph="none" start_char="1423" end_char="1428">events</TOKEN>
<TOKEN id="token-13-4" pos="word" morph="none" start_char="1430" end_char="1433">were</TOKEN>
<TOKEN id="token-13-5" pos="word" morph="none" start_char="1435" end_char="1442">reported</TOKEN>
<TOKEN id="token-13-6" pos="punct" morph="none" start_char="1443" end_char="1443">.</TOKEN>
</SEG>
<SEG id="segment-14" start_char="1446" end_char="1607">
<ORIGINAL_TEXT>In another study, subjects suffering from COVID-19 were divided into two groups with one group receiving ribavirin and the other receiving sofosbuvir/daclatasvir.</ORIGINAL_TEXT>
<TOKEN id="token-14-0" pos="word" morph="none" start_char="1446" end_char="1447">In</TOKEN>
<TOKEN id="token-14-1" pos="word" morph="none" start_char="1449" end_char="1455">another</TOKEN>
<TOKEN id="token-14-2" pos="word" morph="none" start_char="1457" end_char="1461">study</TOKEN>
<TOKEN id="token-14-3" pos="punct" morph="none" start_char="1462" end_char="1462">,</TOKEN>
<TOKEN id="token-14-4" pos="word" morph="none" start_char="1464" end_char="1471">subjects</TOKEN>
<TOKEN id="token-14-5" pos="word" morph="none" start_char="1473" end_char="1481">suffering</TOKEN>
<TOKEN id="token-14-6" pos="word" morph="none" start_char="1483" end_char="1486">from</TOKEN>
<TOKEN id="token-14-7" pos="unknown" morph="none" start_char="1488" end_char="1495">COVID-19</TOKEN>
<TOKEN id="token-14-8" pos="word" morph="none" start_char="1497" end_char="1500">were</TOKEN>
<TOKEN id="token-14-9" pos="word" morph="none" start_char="1502" end_char="1508">divided</TOKEN>
<TOKEN id="token-14-10" pos="word" morph="none" start_char="1510" end_char="1513">into</TOKEN>
<TOKEN id="token-14-11" pos="word" morph="none" start_char="1515" end_char="1517">two</TOKEN>
<TOKEN id="token-14-12" pos="word" morph="none" start_char="1519" end_char="1524">groups</TOKEN>
<TOKEN id="token-14-13" pos="word" morph="none" start_char="1526" end_char="1529">with</TOKEN>
<TOKEN id="token-14-14" pos="word" morph="none" start_char="1531" end_char="1533">one</TOKEN>
<TOKEN id="token-14-15" pos="word" morph="none" start_char="1535" end_char="1539">group</TOKEN>
<TOKEN id="token-14-16" pos="word" morph="none" start_char="1541" end_char="1549">receiving</TOKEN>
<TOKEN id="token-14-17" pos="word" morph="none" start_char="1551" end_char="1559">ribavirin</TOKEN>
<TOKEN id="token-14-18" pos="word" morph="none" start_char="1561" end_char="1563">and</TOKEN>
<TOKEN id="token-14-19" pos="word" morph="none" start_char="1565" end_char="1567">the</TOKEN>
<TOKEN id="token-14-20" pos="word" morph="none" start_char="1569" end_char="1573">other</TOKEN>
<TOKEN id="token-14-21" pos="word" morph="none" start_char="1575" end_char="1583">receiving</TOKEN>
<TOKEN id="token-14-22" pos="unknown" morph="none" start_char="1585" end_char="1606">sofosbuvir/daclatasvir</TOKEN>
<TOKEN id="token-14-23" pos="punct" morph="none" start_char="1607" end_char="1607">.</TOKEN>
</SEG>
<SEG id="segment-15" start_char="1609" end_char="1763">
<ORIGINAL_TEXT>All participants also received the recommended national standard treatment which, at that time, was lopinavir/ritonavir and single-dose hydroxychloroquine.</ORIGINAL_TEXT>
<TOKEN id="token-15-0" pos="word" morph="none" start_char="1609" end_char="1611">All</TOKEN>
<TOKEN id="token-15-1" pos="word" morph="none" start_char="1613" end_char="1624">participants</TOKEN>
<TOKEN id="token-15-2" pos="word" morph="none" start_char="1626" end_char="1629">also</TOKEN>
<TOKEN id="token-15-3" pos="word" morph="none" start_char="1631" end_char="1638">received</TOKEN>
<TOKEN id="token-15-4" pos="word" morph="none" start_char="1640" end_char="1642">the</TOKEN>
<TOKEN id="token-15-5" pos="word" morph="none" start_char="1644" end_char="1654">recommended</TOKEN>
<TOKEN id="token-15-6" pos="word" morph="none" start_char="1656" end_char="1663">national</TOKEN>
<TOKEN id="token-15-7" pos="word" morph="none" start_char="1665" end_char="1672">standard</TOKEN>
<TOKEN id="token-15-8" pos="word" morph="none" start_char="1674" end_char="1682">treatment</TOKEN>
<TOKEN id="token-15-9" pos="word" morph="none" start_char="1684" end_char="1688">which</TOKEN>
<TOKEN id="token-15-10" pos="punct" morph="none" start_char="1689" end_char="1689">,</TOKEN>
<TOKEN id="token-15-11" pos="word" morph="none" start_char="1691" end_char="1692">at</TOKEN>
<TOKEN id="token-15-12" pos="word" morph="none" start_char="1694" end_char="1697">that</TOKEN>
<TOKEN id="token-15-13" pos="word" morph="none" start_char="1699" end_char="1702">time</TOKEN>
<TOKEN id="token-15-14" pos="punct" morph="none" start_char="1703" end_char="1703">,</TOKEN>
<TOKEN id="token-15-15" pos="word" morph="none" start_char="1705" end_char="1707">was</TOKEN>
<TOKEN id="token-15-16" pos="unknown" morph="none" start_char="1709" end_char="1727">lopinavir/ritonavir</TOKEN>
<TOKEN id="token-15-17" pos="word" morph="none" start_char="1729" end_char="1731">and</TOKEN>
<TOKEN id="token-15-18" pos="unknown" morph="none" start_char="1733" end_char="1743">single-dose</TOKEN>
<TOKEN id="token-15-19" pos="word" morph="none" start_char="1745" end_char="1762">hydroxychloroquine</TOKEN>
<TOKEN id="token-15-20" pos="punct" morph="none" start_char="1763" end_char="1763">.</TOKEN>
</SEG>
<SEG id="segment-16" start_char="1766" end_char="1905">
<ORIGINAL_TEXT>The results indicated that median duration of stay was five days for the sofosbuvir/daclatasvir group and nine days for the ribavirin group.</ORIGINAL_TEXT>
<TOKEN id="token-16-0" pos="word" morph="none" start_char="1766" end_char="1768">The</TOKEN>
<TOKEN id="token-16-1" pos="word" morph="none" start_char="1770" end_char="1776">results</TOKEN>
<TOKEN id="token-16-2" pos="word" morph="none" start_char="1778" end_char="1786">indicated</TOKEN>
<TOKEN id="token-16-3" pos="word" morph="none" start_char="1788" end_char="1791">that</TOKEN>
<TOKEN id="token-16-4" pos="word" morph="none" start_char="1793" end_char="1798">median</TOKEN>
<TOKEN id="token-16-5" pos="word" morph="none" start_char="1800" end_char="1807">duration</TOKEN>
<TOKEN id="token-16-6" pos="word" morph="none" start_char="1809" end_char="1810">of</TOKEN>
<TOKEN id="token-16-7" pos="word" morph="none" start_char="1812" end_char="1815">stay</TOKEN>
<TOKEN id="token-16-8" pos="word" morph="none" start_char="1817" end_char="1819">was</TOKEN>
<TOKEN id="token-16-9" pos="word" morph="none" start_char="1821" end_char="1824">five</TOKEN>
<TOKEN id="token-16-10" pos="word" morph="none" start_char="1826" end_char="1829">days</TOKEN>
<TOKEN id="token-16-11" pos="word" morph="none" start_char="1831" end_char="1833">for</TOKEN>
<TOKEN id="token-16-12" pos="word" morph="none" start_char="1835" end_char="1837">the</TOKEN>
<TOKEN id="token-16-13" pos="unknown" morph="none" start_char="1839" end_char="1860">sofosbuvir/daclatasvir</TOKEN>
<TOKEN id="token-16-14" pos="word" morph="none" start_char="1862" end_char="1866">group</TOKEN>
<TOKEN id="token-16-15" pos="word" morph="none" start_char="1868" end_char="1870">and</TOKEN>
<TOKEN id="token-16-16" pos="word" morph="none" start_char="1872" end_char="1875">nine</TOKEN>
<TOKEN id="token-16-17" pos="word" morph="none" start_char="1877" end_char="1880">days</TOKEN>
<TOKEN id="token-16-18" pos="word" morph="none" start_char="1882" end_char="1884">for</TOKEN>
<TOKEN id="token-16-19" pos="word" morph="none" start_char="1886" end_char="1888">the</TOKEN>
<TOKEN id="token-16-20" pos="word" morph="none" start_char="1890" end_char="1898">ribavirin</TOKEN>
<TOKEN id="token-16-21" pos="word" morph="none" start_char="1900" end_char="1904">group</TOKEN>
<TOKEN id="token-16-22" pos="punct" morph="none" start_char="1905" end_char="1905">.</TOKEN>
</SEG>
<SEG id="segment-17" start_char="1907" end_char="1995">
<ORIGINAL_TEXT>The mortality in the sofosbuvir/daclatasvir group was 6% and 33% for the ribavirin group.</ORIGINAL_TEXT>
<TOKEN id="token-17-0" pos="word" morph="none" start_char="1907" end_char="1909">The</TOKEN>
<TOKEN id="token-17-1" pos="word" morph="none" start_char="1911" end_char="1919">mortality</TOKEN>
<TOKEN id="token-17-2" pos="word" morph="none" start_char="1921" end_char="1922">in</TOKEN>
<TOKEN id="token-17-3" pos="word" morph="none" start_char="1924" end_char="1926">the</TOKEN>
<TOKEN id="token-17-4" pos="unknown" morph="none" start_char="1928" end_char="1949">sofosbuvir/daclatasvir</TOKEN>
<TOKEN id="token-17-5" pos="word" morph="none" start_char="1951" end_char="1955">group</TOKEN>
<TOKEN id="token-17-6" pos="word" morph="none" start_char="1957" end_char="1959">was</TOKEN>
<TOKEN id="token-17-7" pos="word" morph="none" start_char="1961" end_char="1961">6</TOKEN>
<TOKEN id="token-17-8" pos="punct" morph="none" start_char="1962" end_char="1962">%</TOKEN>
<TOKEN id="token-17-9" pos="word" morph="none" start_char="1964" end_char="1966">and</TOKEN>
<TOKEN id="token-17-10" pos="word" morph="none" start_char="1968" end_char="1969">33</TOKEN>
<TOKEN id="token-17-11" pos="punct" morph="none" start_char="1970" end_char="1970">%</TOKEN>
<TOKEN id="token-17-12" pos="word" morph="none" start_char="1972" end_char="1974">for</TOKEN>
<TOKEN id="token-17-13" pos="word" morph="none" start_char="1976" end_char="1978">the</TOKEN>
<TOKEN id="token-17-14" pos="word" morph="none" start_char="1980" end_char="1988">ribavirin</TOKEN>
<TOKEN id="token-17-15" pos="word" morph="none" start_char="1990" end_char="1994">group</TOKEN>
<TOKEN id="token-17-16" pos="punct" morph="none" start_char="1995" end_char="1995">.</TOKEN>
</SEG>
<SEG id="segment-18" start_char="1997" end_char="2082">
<ORIGINAL_TEXT>The relative risk of death for patients treated with sofosbuvir/daclatasvir was 0.17%.</ORIGINAL_TEXT>
<TOKEN id="token-18-0" pos="word" morph="none" start_char="1997" end_char="1999">The</TOKEN>
<TOKEN id="token-18-1" pos="word" morph="none" start_char="2001" end_char="2008">relative</TOKEN>
<TOKEN id="token-18-2" pos="word" morph="none" start_char="2010" end_char="2013">risk</TOKEN>
<TOKEN id="token-18-3" pos="word" morph="none" start_char="2015" end_char="2016">of</TOKEN>
<TOKEN id="token-18-4" pos="word" morph="none" start_char="2018" end_char="2022">death</TOKEN>
<TOKEN id="token-18-5" pos="word" morph="none" start_char="2024" end_char="2026">for</TOKEN>
<TOKEN id="token-18-6" pos="word" morph="none" start_char="2028" end_char="2035">patients</TOKEN>
<TOKEN id="token-18-7" pos="word" morph="none" start_char="2037" end_char="2043">treated</TOKEN>
<TOKEN id="token-18-8" pos="word" morph="none" start_char="2045" end_char="2048">with</TOKEN>
<TOKEN id="token-18-9" pos="unknown" morph="none" start_char="2050" end_char="2071">sofosbuvir/daclatasvir</TOKEN>
<TOKEN id="token-18-10" pos="word" morph="none" start_char="2073" end_char="2075">was</TOKEN>
<TOKEN id="token-18-11" pos="unknown" morph="none" start_char="2077" end_char="2080">0.17</TOKEN>
<TOKEN id="token-18-12" pos="punct" morph="none" start_char="2081" end_char="2082">%.</TOKEN>
</SEG>
<SEG id="segment-19" start_char="2085" end_char="2282">
<ORIGINAL_TEXT>The results of these studies suggest that the addition of sofosbuvir and daclatasvir to standard care may reduce the duration of hospital stays for COVID-19 patients compared to standard care alone.</ORIGINAL_TEXT>
<TOKEN id="token-19-0" pos="word" morph="none" start_char="2085" end_char="2087">The</TOKEN>
<TOKEN id="token-19-1" pos="word" morph="none" start_char="2089" end_char="2095">results</TOKEN>
<TOKEN id="token-19-2" pos="word" morph="none" start_char="2097" end_char="2098">of</TOKEN>
<TOKEN id="token-19-3" pos="word" morph="none" start_char="2100" end_char="2104">these</TOKEN>
<TOKEN id="token-19-4" pos="word" morph="none" start_char="2106" end_char="2112">studies</TOKEN>
<TOKEN id="token-19-5" pos="word" morph="none" start_char="2114" end_char="2120">suggest</TOKEN>
<TOKEN id="token-19-6" pos="word" morph="none" start_char="2122" end_char="2125">that</TOKEN>
<TOKEN id="token-19-7" pos="word" morph="none" start_char="2127" end_char="2129">the</TOKEN>
<TOKEN id="token-19-8" pos="word" morph="none" start_char="2131" end_char="2138">addition</TOKEN>
<TOKEN id="token-19-9" pos="word" morph="none" start_char="2140" end_char="2141">of</TOKEN>
<TOKEN id="token-19-10" pos="word" morph="none" start_char="2143" end_char="2152">sofosbuvir</TOKEN>
<TOKEN id="token-19-11" pos="word" morph="none" start_char="2154" end_char="2156">and</TOKEN>
<TOKEN id="token-19-12" pos="word" morph="none" start_char="2158" end_char="2168">daclatasvir</TOKEN>
<TOKEN id="token-19-13" pos="word" morph="none" start_char="2170" end_char="2171">to</TOKEN>
<TOKEN id="token-19-14" pos="word" morph="none" start_char="2173" end_char="2180">standard</TOKEN>
<TOKEN id="token-19-15" pos="word" morph="none" start_char="2182" end_char="2185">care</TOKEN>
<TOKEN id="token-19-16" pos="word" morph="none" start_char="2187" end_char="2189">may</TOKEN>
<TOKEN id="token-19-17" pos="word" morph="none" start_char="2191" end_char="2196">reduce</TOKEN>
<TOKEN id="token-19-18" pos="word" morph="none" start_char="2198" end_char="2200">the</TOKEN>
<TOKEN id="token-19-19" pos="word" morph="none" start_char="2202" end_char="2209">duration</TOKEN>
<TOKEN id="token-19-20" pos="word" morph="none" start_char="2211" end_char="2212">of</TOKEN>
<TOKEN id="token-19-21" pos="word" morph="none" start_char="2214" end_char="2221">hospital</TOKEN>
<TOKEN id="token-19-22" pos="word" morph="none" start_char="2223" end_char="2227">stays</TOKEN>
<TOKEN id="token-19-23" pos="word" morph="none" start_char="2229" end_char="2231">for</TOKEN>
<TOKEN id="token-19-24" pos="unknown" morph="none" start_char="2233" end_char="2240">COVID-19</TOKEN>
<TOKEN id="token-19-25" pos="word" morph="none" start_char="2242" end_char="2249">patients</TOKEN>
<TOKEN id="token-19-26" pos="word" morph="none" start_char="2251" end_char="2258">compared</TOKEN>
<TOKEN id="token-19-27" pos="word" morph="none" start_char="2260" end_char="2261">to</TOKEN>
<TOKEN id="token-19-28" pos="word" morph="none" start_char="2263" end_char="2270">standard</TOKEN>
<TOKEN id="token-19-29" pos="word" morph="none" start_char="2272" end_char="2275">care</TOKEN>
<TOKEN id="token-19-30" pos="word" morph="none" start_char="2277" end_char="2281">alone</TOKEN>
<TOKEN id="token-19-31" pos="punct" morph="none" start_char="2282" end_char="2282">.</TOKEN>
</SEG>
<SEG id="segment-20" start_char="2285" end_char="2361">
<ORIGINAL_TEXT>"Despite the encouraging initial results, it is too early to reach a verdict.</ORIGINAL_TEXT>
<TOKEN id="token-20-0" pos="punct" morph="none" start_char="2285" end_char="2285">"</TOKEN>
<TOKEN id="token-20-1" pos="word" morph="none" start_char="2286" end_char="2292">Despite</TOKEN>
<TOKEN id="token-20-2" pos="word" morph="none" start_char="2294" end_char="2296">the</TOKEN>
<TOKEN id="token-20-3" pos="word" morph="none" start_char="2298" end_char="2308">encouraging</TOKEN>
<TOKEN id="token-20-4" pos="word" morph="none" start_char="2310" end_char="2316">initial</TOKEN>
<TOKEN id="token-20-5" pos="word" morph="none" start_char="2318" end_char="2324">results</TOKEN>
<TOKEN id="token-20-6" pos="punct" morph="none" start_char="2325" end_char="2325">,</TOKEN>
<TOKEN id="token-20-7" pos="word" morph="none" start_char="2327" end_char="2328">it</TOKEN>
<TOKEN id="token-20-8" pos="word" morph="none" start_char="2330" end_char="2331">is</TOKEN>
<TOKEN id="token-20-9" pos="word" morph="none" start_char="2333" end_char="2335">too</TOKEN>
<TOKEN id="token-20-10" pos="word" morph="none" start_char="2337" end_char="2341">early</TOKEN>
<TOKEN id="token-20-11" pos="word" morph="none" start_char="2343" end_char="2344">to</TOKEN>
<TOKEN id="token-20-12" pos="word" morph="none" start_char="2346" end_char="2350">reach</TOKEN>
<TOKEN id="token-20-13" pos="word" morph="none" start_char="2352" end_char="2352">a</TOKEN>
<TOKEN id="token-20-14" pos="word" morph="none" start_char="2354" end_char="2360">verdict</TOKEN>
<TOKEN id="token-20-15" pos="punct" morph="none" start_char="2361" end_char="2361">.</TOKEN>
</SEG>
<SEG id="segment-21" start_char="2363" end_char="2526">
<ORIGINAL_TEXT>Larger, well-designed studies are required to confirm our results," said Shahin Merat, the lead author of one of the Journal of Antimicrobial Chemotherapy articles.</ORIGINAL_TEXT>
<TOKEN id="token-21-0" pos="word" morph="none" start_char="2363" end_char="2368">Larger</TOKEN>
<TOKEN id="token-21-1" pos="punct" morph="none" start_char="2369" end_char="2369">,</TOKEN>
<TOKEN id="token-21-2" pos="unknown" morph="none" start_char="2371" end_char="2383">well-designed</TOKEN>
<TOKEN id="token-21-3" pos="word" morph="none" start_char="2385" end_char="2391">studies</TOKEN>
<TOKEN id="token-21-4" pos="word" morph="none" start_char="2393" end_char="2395">are</TOKEN>
<TOKEN id="token-21-5" pos="word" morph="none" start_char="2397" end_char="2404">required</TOKEN>
<TOKEN id="token-21-6" pos="word" morph="none" start_char="2406" end_char="2407">to</TOKEN>
<TOKEN id="token-21-7" pos="word" morph="none" start_char="2409" end_char="2415">confirm</TOKEN>
<TOKEN id="token-21-8" pos="word" morph="none" start_char="2417" end_char="2419">our</TOKEN>
<TOKEN id="token-21-9" pos="word" morph="none" start_char="2421" end_char="2427">results</TOKEN>
<TOKEN id="token-21-10" pos="punct" morph="none" start_char="2428" end_char="2429">,"</TOKEN>
<TOKEN id="token-21-11" pos="word" morph="none" start_char="2431" end_char="2434">said</TOKEN>
<TOKEN id="token-21-12" pos="word" morph="none" start_char="2436" end_char="2441">Shahin</TOKEN>
<TOKEN id="token-21-13" pos="word" morph="none" start_char="2443" end_char="2447">Merat</TOKEN>
<TOKEN id="token-21-14" pos="punct" morph="none" start_char="2448" end_char="2448">,</TOKEN>
<TOKEN id="token-21-15" pos="word" morph="none" start_char="2450" end_char="2452">the</TOKEN>
<TOKEN id="token-21-16" pos="word" morph="none" start_char="2454" end_char="2457">lead</TOKEN>
<TOKEN id="token-21-17" pos="word" morph="none" start_char="2459" end_char="2464">author</TOKEN>
<TOKEN id="token-21-18" pos="word" morph="none" start_char="2466" end_char="2467">of</TOKEN>
<TOKEN id="token-21-19" pos="word" morph="none" start_char="2469" end_char="2471">one</TOKEN>
<TOKEN id="token-21-20" pos="word" morph="none" start_char="2473" end_char="2474">of</TOKEN>
<TOKEN id="token-21-21" pos="word" morph="none" start_char="2476" end_char="2478">the</TOKEN>
<TOKEN id="token-21-22" pos="word" morph="none" start_char="2480" end_char="2486">Journal</TOKEN>
<TOKEN id="token-21-23" pos="word" morph="none" start_char="2488" end_char="2489">of</TOKEN>
<TOKEN id="token-21-24" pos="word" morph="none" start_char="2491" end_char="2503">Antimicrobial</TOKEN>
<TOKEN id="token-21-25" pos="word" morph="none" start_char="2505" end_char="2516">Chemotherapy</TOKEN>
<TOKEN id="token-21-26" pos="word" morph="none" start_char="2518" end_char="2525">articles</TOKEN>
<TOKEN id="token-21-27" pos="punct" morph="none" start_char="2526" end_char="2526">.</TOKEN>
</SEG>
<SEG id="segment-22" start_char="2528" end_char="2704">
<ORIGINAL_TEXT>"A network of five randomised clinical trials has been set up, to test sofosbuvir plus daclatasvir in over 2000 patients with COVID-19, in Iran, Brazil, Egypt, and South Africa.</ORIGINAL_TEXT>
<TOKEN id="token-22-0" pos="punct" morph="none" start_char="2528" end_char="2528">"</TOKEN>
<TOKEN id="token-22-1" pos="word" morph="none" start_char="2529" end_char="2529">A</TOKEN>
<TOKEN id="token-22-2" pos="word" morph="none" start_char="2531" end_char="2537">network</TOKEN>
<TOKEN id="token-22-3" pos="word" morph="none" start_char="2539" end_char="2540">of</TOKEN>
<TOKEN id="token-22-4" pos="word" morph="none" start_char="2542" end_char="2545">five</TOKEN>
<TOKEN id="token-22-5" pos="word" morph="none" start_char="2547" end_char="2556">randomised</TOKEN>
<TOKEN id="token-22-6" pos="word" morph="none" start_char="2558" end_char="2565">clinical</TOKEN>
<TOKEN id="token-22-7" pos="word" morph="none" start_char="2567" end_char="2572">trials</TOKEN>
<TOKEN id="token-22-8" pos="word" morph="none" start_char="2574" end_char="2576">has</TOKEN>
<TOKEN id="token-22-9" pos="word" morph="none" start_char="2578" end_char="2581">been</TOKEN>
<TOKEN id="token-22-10" pos="word" morph="none" start_char="2583" end_char="2585">set</TOKEN>
<TOKEN id="token-22-11" pos="word" morph="none" start_char="2587" end_char="2588">up</TOKEN>
<TOKEN id="token-22-12" pos="punct" morph="none" start_char="2589" end_char="2589">,</TOKEN>
<TOKEN id="token-22-13" pos="word" morph="none" start_char="2591" end_char="2592">to</TOKEN>
<TOKEN id="token-22-14" pos="word" morph="none" start_char="2594" end_char="2597">test</TOKEN>
<TOKEN id="token-22-15" pos="word" morph="none" start_char="2599" end_char="2608">sofosbuvir</TOKEN>
<TOKEN id="token-22-16" pos="word" morph="none" start_char="2610" end_char="2613">plus</TOKEN>
<TOKEN id="token-22-17" pos="word" morph="none" start_char="2615" end_char="2625">daclatasvir</TOKEN>
<TOKEN id="token-22-18" pos="word" morph="none" start_char="2627" end_char="2628">in</TOKEN>
<TOKEN id="token-22-19" pos="word" morph="none" start_char="2630" end_char="2633">over</TOKEN>
<TOKEN id="token-22-20" pos="word" morph="none" start_char="2635" end_char="2638">2000</TOKEN>
<TOKEN id="token-22-21" pos="word" morph="none" start_char="2640" end_char="2647">patients</TOKEN>
<TOKEN id="token-22-22" pos="word" morph="none" start_char="2649" end_char="2652">with</TOKEN>
<TOKEN id="token-22-23" pos="unknown" morph="none" start_char="2654" end_char="2661">COVID-19</TOKEN>
<TOKEN id="token-22-24" pos="punct" morph="none" start_char="2662" end_char="2662">,</TOKEN>
<TOKEN id="token-22-25" pos="word" morph="none" start_char="2664" end_char="2665">in</TOKEN>
<TOKEN id="token-22-26" pos="word" morph="none" start_char="2667" end_char="2670">Iran</TOKEN>
<TOKEN id="token-22-27" pos="punct" morph="none" start_char="2671" end_char="2671">,</TOKEN>
<TOKEN id="token-22-28" pos="word" morph="none" start_char="2673" end_char="2678">Brazil</TOKEN>
<TOKEN id="token-22-29" pos="punct" morph="none" start_char="2679" end_char="2679">,</TOKEN>
<TOKEN id="token-22-30" pos="word" morph="none" start_char="2681" end_char="2685">Egypt</TOKEN>
<TOKEN id="token-22-31" pos="punct" morph="none" start_char="2686" end_char="2686">,</TOKEN>
<TOKEN id="token-22-32" pos="word" morph="none" start_char="2688" end_char="2690">and</TOKEN>
<TOKEN id="token-22-33" pos="word" morph="none" start_char="2692" end_char="2696">South</TOKEN>
<TOKEN id="token-22-34" pos="word" morph="none" start_char="2698" end_char="2703">Africa</TOKEN>
<TOKEN id="token-22-35" pos="punct" morph="none" start_char="2704" end_char="2704">.</TOKEN>
</SEG>
<SEG id="segment-23" start_char="2706" end_char="2787">
<ORIGINAL_TEXT>By October, we should know if this treatment could be approved for worldwide use."</ORIGINAL_TEXT>
<TOKEN id="token-23-0" pos="word" morph="none" start_char="2706" end_char="2707">By</TOKEN>
<TOKEN id="token-23-1" pos="word" morph="none" start_char="2709" end_char="2715">October</TOKEN>
<TOKEN id="token-23-2" pos="punct" morph="none" start_char="2716" end_char="2716">,</TOKEN>
<TOKEN id="token-23-3" pos="word" morph="none" start_char="2718" end_char="2719">we</TOKEN>
<TOKEN id="token-23-4" pos="word" morph="none" start_char="2721" end_char="2726">should</TOKEN>
<TOKEN id="token-23-5" pos="word" morph="none" start_char="2728" end_char="2731">know</TOKEN>
<TOKEN id="token-23-6" pos="word" morph="none" start_char="2733" end_char="2734">if</TOKEN>
<TOKEN id="token-23-7" pos="word" morph="none" start_char="2736" end_char="2739">this</TOKEN>
<TOKEN id="token-23-8" pos="word" morph="none" start_char="2741" end_char="2749">treatment</TOKEN>
<TOKEN id="token-23-9" pos="word" morph="none" start_char="2751" end_char="2755">could</TOKEN>
<TOKEN id="token-23-10" pos="word" morph="none" start_char="2757" end_char="2758">be</TOKEN>
<TOKEN id="token-23-11" pos="word" morph="none" start_char="2760" end_char="2767">approved</TOKEN>
<TOKEN id="token-23-12" pos="word" morph="none" start_char="2769" end_char="2771">for</TOKEN>
<TOKEN id="token-23-13" pos="word" morph="none" start_char="2773" end_char="2781">worldwide</TOKEN>
<TOKEN id="token-23-14" pos="word" morph="none" start_char="2783" end_char="2785">use</TOKEN>
<TOKEN id="token-23-15" pos="punct" morph="none" start_char="2786" end_char="2787">."</TOKEN>
</SEG>
<SEG id="segment-24" start_char="2790" end_char="2792">
<ORIGINAL_TEXT>###</ORIGINAL_TEXT>
<TOKEN id="token-24-0" pos="tag" morph="none" start_char="2790" end_char="2792">###</TOKEN>
</SEG>
<SEG id="segment-25" start_char="2795" end_char="3340">
<ORIGINAL_TEXT>The papers "The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19", "Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19)," and "Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial," will be available (at Midnight (EST) on August 19th at:</ORIGINAL_TEXT>
<TOKEN id="token-25-0" pos="word" morph="none" start_char="2795" end_char="2797">The</TOKEN>
<TOKEN id="token-25-1" pos="word" morph="none" start_char="2799" end_char="2804">papers</TOKEN>
<TOKEN id="token-25-2" pos="punct" morph="none" start_char="2806" end_char="2806">"</TOKEN>
<TOKEN id="token-25-3" pos="word" morph="none" start_char="2807" end_char="2809">The</TOKEN>
<TOKEN id="token-25-4" pos="word" morph="none" start_char="2811" end_char="2816">impact</TOKEN>
<TOKEN id="token-25-5" pos="word" morph="none" start_char="2818" end_char="2819">of</TOKEN>
<TOKEN id="token-25-6" pos="unknown" morph="none" start_char="2821" end_char="2842">sofosbuvir/daclatasvir</TOKEN>
<TOKEN id="token-25-7" pos="word" morph="none" start_char="2844" end_char="2845">or</TOKEN>
<TOKEN id="token-25-8" pos="word" morph="none" start_char="2847" end_char="2855">ribavirin</TOKEN>
<TOKEN id="token-25-9" pos="word" morph="none" start_char="2857" end_char="2858">in</TOKEN>
<TOKEN id="token-25-10" pos="word" morph="none" start_char="2860" end_char="2867">patients</TOKEN>
<TOKEN id="token-25-11" pos="word" morph="none" start_char="2869" end_char="2872">with</TOKEN>
<TOKEN id="token-25-12" pos="word" morph="none" start_char="2874" end_char="2879">severe</TOKEN>
<TOKEN id="token-25-13" pos="unknown" morph="none" start_char="2881" end_char="2888">COVID-19</TOKEN>
<TOKEN id="token-25-14" pos="punct" morph="none" start_char="2889" end_char="2890">",</TOKEN>
<TOKEN id="token-25-15" pos="punct" morph="none" start_char="2892" end_char="2892">"</TOKEN>
<TOKEN id="token-25-16" pos="word" morph="none" start_char="2893" end_char="2902">Sofosbuvir</TOKEN>
<TOKEN id="token-25-17" pos="word" morph="none" start_char="2904" end_char="2906">and</TOKEN>
<TOKEN id="token-25-18" pos="word" morph="none" start_char="2908" end_char="2918">daclatasvir</TOKEN>
<TOKEN id="token-25-19" pos="word" morph="none" start_char="2920" end_char="2927">compared</TOKEN>
<TOKEN id="token-25-20" pos="word" morph="none" start_char="2929" end_char="2932">with</TOKEN>
<TOKEN id="token-25-21" pos="word" morph="none" start_char="2934" end_char="2941">standard</TOKEN>
<TOKEN id="token-25-22" pos="word" morph="none" start_char="2943" end_char="2944">of</TOKEN>
<TOKEN id="token-25-23" pos="word" morph="none" start_char="2946" end_char="2949">care</TOKEN>
<TOKEN id="token-25-24" pos="word" morph="none" start_char="2951" end_char="2952">in</TOKEN>
<TOKEN id="token-25-25" pos="word" morph="none" start_char="2954" end_char="2956">the</TOKEN>
<TOKEN id="token-25-26" pos="word" morph="none" start_char="2958" end_char="2966">treatment</TOKEN>
<TOKEN id="token-25-27" pos="word" morph="none" start_char="2968" end_char="2969">of</TOKEN>
<TOKEN id="token-25-28" pos="word" morph="none" start_char="2971" end_char="2978">patients</TOKEN>
<TOKEN id="token-25-29" pos="word" morph="none" start_char="2980" end_char="2987">admitted</TOKEN>
<TOKEN id="token-25-30" pos="word" morph="none" start_char="2989" end_char="2990">to</TOKEN>
<TOKEN id="token-25-31" pos="word" morph="none" start_char="2992" end_char="2999">hospital</TOKEN>
<TOKEN id="token-25-32" pos="word" morph="none" start_char="3001" end_char="3004">with</TOKEN>
<TOKEN id="token-25-33" pos="word" morph="none" start_char="3006" end_char="3013">moderate</TOKEN>
<TOKEN id="token-25-34" pos="word" morph="none" start_char="3015" end_char="3016">or</TOKEN>
<TOKEN id="token-25-35" pos="word" morph="none" start_char="3018" end_char="3023">severe</TOKEN>
<TOKEN id="token-25-36" pos="word" morph="none" start_char="3025" end_char="3035">coronavirus</TOKEN>
<TOKEN id="token-25-37" pos="word" morph="none" start_char="3037" end_char="3045">infection</TOKEN>
<TOKEN id="token-25-38" pos="punct" morph="none" start_char="3047" end_char="3047">(</TOKEN>
<TOKEN id="token-25-39" pos="unknown" morph="none" start_char="3048" end_char="3055">COVID-19</TOKEN>
<TOKEN id="token-25-40" pos="punct" morph="none" start_char="3056" end_char="3058">),"</TOKEN>
<TOKEN id="token-25-41" pos="word" morph="none" start_char="3060" end_char="3062">and</TOKEN>
<TOKEN id="token-25-42" pos="punct" morph="none" start_char="3064" end_char="3064">"</TOKEN>
<TOKEN id="token-25-43" pos="word" morph="none" start_char="3065" end_char="3074">Evaluation</TOKEN>
<TOKEN id="token-25-44" pos="word" morph="none" start_char="3076" end_char="3077">of</TOKEN>
<TOKEN id="token-25-45" pos="word" morph="none" start_char="3079" end_char="3081">the</TOKEN>
<TOKEN id="token-25-46" pos="word" morph="none" start_char="3083" end_char="3090">efficacy</TOKEN>
<TOKEN id="token-25-47" pos="word" morph="none" start_char="3092" end_char="3093">of</TOKEN>
<TOKEN id="token-25-48" pos="word" morph="none" start_char="3095" end_char="3104">sofosbuvir</TOKEN>
<TOKEN id="token-25-49" pos="word" morph="none" start_char="3106" end_char="3109">plus</TOKEN>
<TOKEN id="token-25-50" pos="word" morph="none" start_char="3111" end_char="3121">daclatasvir</TOKEN>
<TOKEN id="token-25-51" pos="word" morph="none" start_char="3123" end_char="3124">in</TOKEN>
<TOKEN id="token-25-52" pos="word" morph="none" start_char="3126" end_char="3136">combination</TOKEN>
<TOKEN id="token-25-53" pos="word" morph="none" start_char="3138" end_char="3141">with</TOKEN>
<TOKEN id="token-25-54" pos="word" morph="none" start_char="3143" end_char="3151">ribavirin</TOKEN>
<TOKEN id="token-25-55" pos="word" morph="none" start_char="3153" end_char="3155">for</TOKEN>
<TOKEN id="token-25-56" pos="word" morph="none" start_char="3157" end_char="3168">hospitalized</TOKEN>
<TOKEN id="token-25-57" pos="unknown" morph="none" start_char="3170" end_char="3177">COVID-19</TOKEN>
<TOKEN id="token-25-58" pos="word" morph="none" start_char="3179" end_char="3186">patients</TOKEN>
<TOKEN id="token-25-59" pos="word" morph="none" start_char="3188" end_char="3191">with</TOKEN>
<TOKEN id="token-25-60" pos="word" morph="none" start_char="3193" end_char="3200">moderate</TOKEN>
<TOKEN id="token-25-61" pos="word" morph="none" start_char="3202" end_char="3208">disease</TOKEN>
<TOKEN id="token-25-62" pos="word" morph="none" start_char="3210" end_char="3217">compared</TOKEN>
<TOKEN id="token-25-63" pos="word" morph="none" start_char="3219" end_char="3222">with</TOKEN>
<TOKEN id="token-25-64" pos="word" morph="none" start_char="3224" end_char="3231">standard</TOKEN>
<TOKEN id="token-25-65" pos="word" morph="none" start_char="3233" end_char="3236">care</TOKEN>
<TOKEN id="token-25-66" pos="punct" morph="none" start_char="3237" end_char="3237">:</TOKEN>
<TOKEN id="token-25-67" pos="word" morph="none" start_char="3239" end_char="3239">a</TOKEN>
<TOKEN id="token-25-68" pos="unknown" morph="none" start_char="3241" end_char="3253">single-centre</TOKEN>
<TOKEN id="token-25-69" pos="punct" morph="none" start_char="3254" end_char="3254">,</TOKEN>
<TOKEN id="token-25-70" pos="word" morph="none" start_char="3256" end_char="3265">randomized</TOKEN>
<TOKEN id="token-25-71" pos="word" morph="none" start_char="3267" end_char="3276">controlled</TOKEN>
<TOKEN id="token-25-72" pos="word" morph="none" start_char="3278" end_char="3282">trial</TOKEN>
<TOKEN id="token-25-73" pos="punct" morph="none" start_char="3283" end_char="3284">,"</TOKEN>
<TOKEN id="token-25-74" pos="word" morph="none" start_char="3286" end_char="3289">will</TOKEN>
<TOKEN id="token-25-75" pos="word" morph="none" start_char="3291" end_char="3292">be</TOKEN>
<TOKEN id="token-25-76" pos="word" morph="none" start_char="3294" end_char="3302">available</TOKEN>
<TOKEN id="token-25-77" pos="punct" morph="none" start_char="3304" end_char="3304">(</TOKEN>
<TOKEN id="token-25-78" pos="word" morph="none" start_char="3305" end_char="3306">at</TOKEN>
<TOKEN id="token-25-79" pos="word" morph="none" start_char="3308" end_char="3315">Midnight</TOKEN>
<TOKEN id="token-25-80" pos="punct" morph="none" start_char="3317" end_char="3317">(</TOKEN>
<TOKEN id="token-25-81" pos="word" morph="none" start_char="3318" end_char="3320">EST</TOKEN>
<TOKEN id="token-25-82" pos="punct" morph="none" start_char="3321" end_char="3321">)</TOKEN>
<TOKEN id="token-25-83" pos="word" morph="none" start_char="3323" end_char="3324">on</TOKEN>
<TOKEN id="token-25-84" pos="word" morph="none" start_char="3326" end_char="3331">August</TOKEN>
<TOKEN id="token-25-85" pos="word" morph="none" start_char="3333" end_char="3336">19th</TOKEN>
<TOKEN id="token-25-86" pos="word" morph="none" start_char="3338" end_char="3339">at</TOKEN>
<TOKEN id="token-25-87" pos="punct" morph="none" start_char="3340" end_char="3340">:</TOKEN>
</SEG>
<SEG id="segment-26" start_char="3343" end_char="3413">
<ORIGINAL_TEXT>doi:10.1093/jac/dkaa331 doi:10.1093/jac/dkaa332 doi:10.1093/jac/dkaa334</ORIGINAL_TEXT>
<TOKEN id="token-26-0" pos="unknown" morph="none" start_char="3343" end_char="3365">doi:10.1093/jac/dkaa331</TOKEN>
<TOKEN id="token-26-1" pos="unknown" morph="none" start_char="3367" end_char="3389">doi:10.1093/jac/dkaa332</TOKEN>
<TOKEN id="token-26-2" pos="unknown" morph="none" start_char="3391" end_char="3413">doi:10.1093/jac/dkaa334</TOKEN>
</SEG>
<SEG id="segment-27" start_char="3416" end_char="3440">
<ORIGINAL_TEXT>Direct correspondence to:</ORIGINAL_TEXT>
<TOKEN id="token-27-0" pos="word" morph="none" start_char="3416" end_char="3421">Direct</TOKEN>
<TOKEN id="token-27-1" pos="word" morph="none" start_char="3423" end_char="3436">correspondence</TOKEN>
<TOKEN id="token-27-2" pos="word" morph="none" start_char="3438" end_char="3439">to</TOKEN>
<TOKEN id="token-27-3" pos="punct" morph="none" start_char="3440" end_char="3440">:</TOKEN>
</SEG>
<SEG id="segment-28" start_char="3443" end_char="3585">
<ORIGINAL_TEXT>Dr Andrew Hill Senior Visiting Research Fellow, Liverpool University 70 Pembroke Place Liverpool L69 3GF, UNITED KINGDOM andrewhillmv@gmail.com</ORIGINAL_TEXT>
<TOKEN id="token-28-0" pos="word" morph="none" start_char="3443" end_char="3444">Dr</TOKEN>
<TOKEN id="token-28-1" pos="word" morph="none" start_char="3446" end_char="3451">Andrew</TOKEN>
<TOKEN id="token-28-2" pos="word" morph="none" start_char="3453" end_char="3456">Hill</TOKEN>
<TOKEN id="token-28-3" pos="word" morph="none" start_char="3458" end_char="3463">Senior</TOKEN>
<TOKEN id="token-28-4" pos="word" morph="none" start_char="3465" end_char="3472">Visiting</TOKEN>
<TOKEN id="token-28-5" pos="word" morph="none" start_char="3474" end_char="3481">Research</TOKEN>
<TOKEN id="token-28-6" pos="word" morph="none" start_char="3483" end_char="3488">Fellow</TOKEN>
<TOKEN id="token-28-7" pos="punct" morph="none" start_char="3489" end_char="3489">,</TOKEN>
<TOKEN id="token-28-8" pos="word" morph="none" start_char="3491" end_char="3499">Liverpool</TOKEN>
<TOKEN id="token-28-9" pos="word" morph="none" start_char="3501" end_char="3510">University</TOKEN>
<TOKEN id="token-28-10" pos="word" morph="none" start_char="3512" end_char="3513">70</TOKEN>
<TOKEN id="token-28-11" pos="word" morph="none" start_char="3515" end_char="3522">Pembroke</TOKEN>
<TOKEN id="token-28-12" pos="word" morph="none" start_char="3524" end_char="3528">Place</TOKEN>
<TOKEN id="token-28-13" pos="word" morph="none" start_char="3530" end_char="3538">Liverpool</TOKEN>
<TOKEN id="token-28-14" pos="word" morph="none" start_char="3540" end_char="3542">L69</TOKEN>
<TOKEN id="token-28-15" pos="word" morph="none" start_char="3544" end_char="3546">3GF</TOKEN>
<TOKEN id="token-28-16" pos="punct" morph="none" start_char="3547" end_char="3547">,</TOKEN>
<TOKEN id="token-28-17" pos="word" morph="none" start_char="3549" end_char="3554">UNITED</TOKEN>
<TOKEN id="token-28-18" pos="word" morph="none" start_char="3556" end_char="3562">KINGDOM</TOKEN>
<TOKEN id="token-28-19" pos="unknown" morph="none" start_char="3564" end_char="3585">andrewhillmv@gmail.com</TOKEN>
</SEG>
<SEG id="segment-29" start_char="3588" end_char="3591">
<ORIGINAL_TEXT>(or)</ORIGINAL_TEXT>
<TOKEN id="token-29-0" pos="punct" morph="none" start_char="3588" end_char="3588">(</TOKEN>
<TOKEN id="token-29-1" pos="word" morph="none" start_char="3589" end_char="3590">or</TOKEN>
<TOKEN id="token-29-2" pos="punct" morph="none" start_char="3591" end_char="3591">)</TOKEN>
</SEG>
<SEG id="segment-30" start_char="3594" end_char="3721">
<ORIGINAL_TEXT>Shahin Merat Digestive Disease Research Institute, Tehran University of Medical Sciences Tehran, 32, IRAN shahin.merat@gmail.com</ORIGINAL_TEXT>
<TOKEN id="token-30-0" pos="word" morph="none" start_char="3594" end_char="3599">Shahin</TOKEN>
<TOKEN id="token-30-1" pos="word" morph="none" start_char="3601" end_char="3605">Merat</TOKEN>
<TOKEN id="token-30-2" pos="word" morph="none" start_char="3607" end_char="3615">Digestive</TOKEN>
<TOKEN id="token-30-3" pos="word" morph="none" start_char="3617" end_char="3623">Disease</TOKEN>
<TOKEN id="token-30-4" pos="word" morph="none" start_char="3625" end_char="3632">Research</TOKEN>
<TOKEN id="token-30-5" pos="word" morph="none" start_char="3634" end_char="3642">Institute</TOKEN>
<TOKEN id="token-30-6" pos="punct" morph="none" start_char="3643" end_char="3643">,</TOKEN>
<TOKEN id="token-30-7" pos="word" morph="none" start_char="3645" end_char="3650">Tehran</TOKEN>
<TOKEN id="token-30-8" pos="word" morph="none" start_char="3652" end_char="3661">University</TOKEN>
<TOKEN id="token-30-9" pos="word" morph="none" start_char="3663" end_char="3664">of</TOKEN>
<TOKEN id="token-30-10" pos="word" morph="none" start_char="3666" end_char="3672">Medical</TOKEN>
<TOKEN id="token-30-11" pos="word" morph="none" start_char="3674" end_char="3681">Sciences</TOKEN>
<TOKEN id="token-30-12" pos="word" morph="none" start_char="3683" end_char="3688">Tehran</TOKEN>
<TOKEN id="token-30-13" pos="punct" morph="none" start_char="3689" end_char="3689">,</TOKEN>
<TOKEN id="token-30-14" pos="word" morph="none" start_char="3691" end_char="3692">32</TOKEN>
<TOKEN id="token-30-15" pos="punct" morph="none" start_char="3693" end_char="3693">,</TOKEN>
<TOKEN id="token-30-16" pos="word" morph="none" start_char="3695" end_char="3698">IRAN</TOKEN>
<TOKEN id="token-30-17" pos="unknown" morph="none" start_char="3700" end_char="3721">shahin.merat@gmail.com</TOKEN>
</SEG>
<SEG id="segment-31" start_char="3724" end_char="3755">
<ORIGINAL_TEXT>Disclaimer: AAAS and EurekAlert!</ORIGINAL_TEXT>
<TOKEN id="token-31-0" pos="word" morph="none" start_char="3724" end_char="3733">Disclaimer</TOKEN>
<TOKEN id="token-31-1" pos="punct" morph="none" start_char="3734" end_char="3734">:</TOKEN>
<TOKEN id="token-31-2" pos="word" morph="none" start_char="3736" end_char="3739">AAAS</TOKEN>
<TOKEN id="token-31-3" pos="word" morph="none" start_char="3741" end_char="3743">and</TOKEN>
<TOKEN id="token-31-4" pos="word" morph="none" start_char="3745" end_char="3754">EurekAlert</TOKEN>
<TOKEN id="token-31-5" pos="punct" morph="none" start_char="3755" end_char="3755">!</TOKEN>
</SEG>
<SEG id="segment-32" start_char="3757" end_char="3831">
<ORIGINAL_TEXT>are not responsible for the accuracy of news releases posted to EurekAlert!</ORIGINAL_TEXT>
<TOKEN id="token-32-0" pos="word" morph="none" start_char="3757" end_char="3759">are</TOKEN>
<TOKEN id="token-32-1" pos="word" morph="none" start_char="3761" end_char="3763">not</TOKEN>
<TOKEN id="token-32-2" pos="word" morph="none" start_char="3765" end_char="3775">responsible</TOKEN>
<TOKEN id="token-32-3" pos="word" morph="none" start_char="3777" end_char="3779">for</TOKEN>
<TOKEN id="token-32-4" pos="word" morph="none" start_char="3781" end_char="3783">the</TOKEN>
<TOKEN id="token-32-5" pos="word" morph="none" start_char="3785" end_char="3792">accuracy</TOKEN>
<TOKEN id="token-32-6" pos="word" morph="none" start_char="3794" end_char="3795">of</TOKEN>
<TOKEN id="token-32-7" pos="word" morph="none" start_char="3797" end_char="3800">news</TOKEN>
<TOKEN id="token-32-8" pos="word" morph="none" start_char="3802" end_char="3809">releases</TOKEN>
<TOKEN id="token-32-9" pos="word" morph="none" start_char="3811" end_char="3816">posted</TOKEN>
<TOKEN id="token-32-10" pos="word" morph="none" start_char="3818" end_char="3819">to</TOKEN>
<TOKEN id="token-32-11" pos="word" morph="none" start_char="3821" end_char="3830">EurekAlert</TOKEN>
<TOKEN id="token-32-12" pos="punct" morph="none" start_char="3831" end_char="3831">!</TOKEN>
</SEG>
<SEG id="segment-33" start_char="3833" end_char="3925">
<ORIGINAL_TEXT>by contributing institutions or for the use of any information through the EurekAlert system.</ORIGINAL_TEXT>
<TOKEN id="token-33-0" pos="word" morph="none" start_char="3833" end_char="3834">by</TOKEN>
<TOKEN id="token-33-1" pos="word" morph="none" start_char="3836" end_char="3847">contributing</TOKEN>
<TOKEN id="token-33-2" pos="word" morph="none" start_char="3849" end_char="3860">institutions</TOKEN>
<TOKEN id="token-33-3" pos="word" morph="none" start_char="3862" end_char="3863">or</TOKEN>
<TOKEN id="token-33-4" pos="word" morph="none" start_char="3865" end_char="3867">for</TOKEN>
<TOKEN id="token-33-5" pos="word" morph="none" start_char="3869" end_char="3871">the</TOKEN>
<TOKEN id="token-33-6" pos="word" morph="none" start_char="3873" end_char="3875">use</TOKEN>
<TOKEN id="token-33-7" pos="word" morph="none" start_char="3877" end_char="3878">of</TOKEN>
<TOKEN id="token-33-8" pos="word" morph="none" start_char="3880" end_char="3882">any</TOKEN>
<TOKEN id="token-33-9" pos="word" morph="none" start_char="3884" end_char="3894">information</TOKEN>
<TOKEN id="token-33-10" pos="word" morph="none" start_char="3896" end_char="3902">through</TOKEN>
<TOKEN id="token-33-11" pos="word" morph="none" start_char="3904" end_char="3906">the</TOKEN>
<TOKEN id="token-33-12" pos="word" morph="none" start_char="3908" end_char="3917">EurekAlert</TOKEN>
<TOKEN id="token-33-13" pos="word" morph="none" start_char="3919" end_char="3924">system</TOKEN>
<TOKEN id="token-33-14" pos="punct" morph="none" start_char="3925" end_char="3925">.</TOKEN>
</SEG>
</TEXT>
</DOC>
</LCTL_TEXT>
